In-vitro and in-vivo activity of rifabutin against Toxoplasma gondii

P. B. Olliaro, G. Gorini, D. Jabes, A. Regazzetti, R. Rossi, A. Marchetti, C. Tinelli, C. Della Bruna

Research output: Contribution to journalArticle

Abstract

The activity of rifabutin against Toxoplasma gondii was investigated in vitro and in vivo. One set of in-vitro studies used either a low virulence or a high virulence T. gondii strain subcultured in drug-free conditions after exposure to various drug concentrations. No parasite growth was observed after subculture at 1 month after exposure to 6 mg/L of rifabutin for the low virulence and 12 mg/L for the high virulence strain. The IC 50 of rifabutin was 26.5 mg/L in a different series of experiments (using an enzyme-linked immunoassay) and the T. gondii high virulence strain. In similar experiments with clarithromycin, low virulence and high virulence parasites grew in drug-free subcultures following exposure to drug concentrations as high as 100mg/L; the IC 50 of clarithromycin exceeded 100mg/L for the high virulence strain. In the acute toxoplasmosis murine model, mice received a 12 day treatment starting 5 days before infection with high virulence parasites. Survival was significantly improved compared with untreated controls in response to 50, 100 and 200 mg/kg/day rifabutin and 100 and 200 (but not 50) mg/kg/day clarithromycin, and with the combination of the two drugs at 25, 50 and 100 mg/kg/day. Survival was significantly improved when combination therapy was administered. The calculated ED 50 values (mg/kg/day) were 160.5 for rifabutin, 119.4 for clarithromycin, and 114.8 for the combination. In the present experimental conditions rifabutin proved effective in vitro and in vivo against T. gondii and showed potentiation with clarithromycin in vivo.

Original languageEnglish
Pages (from-to)649-657
Number of pages9
JournalJournal of Antimicrobial Chemotherapy
Volume34
Issue number5
Publication statusPublished - 1994

Fingerprint

Rifabutin
Toxoplasma
Virulence
Drugs
Clarithromycin
Parasites
Immunoassay
Pharmaceutical Preparations
Enzymes
Acute
Experiments
Therapy
Experiment
Infection
Mouse
In Vitro Techniques
Toxoplasma gondii
Toxoplasmosis
Drug Combinations
Series

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Microbiology
  • Applied Mathematics
  • Infectious Diseases
  • Pharmacology (medical)
  • Physiology (medical)
  • Pharmacology

Cite this

Olliaro, P. B., Gorini, G., Jabes, D., Regazzetti, A., Rossi, R., Marchetti, A., ... Della Bruna, C. (1994). In-vitro and in-vivo activity of rifabutin against Toxoplasma gondii. Journal of Antimicrobial Chemotherapy, 34(5), 649-657.

In-vitro and in-vivo activity of rifabutin against Toxoplasma gondii. / Olliaro, P. B.; Gorini, G.; Jabes, D.; Regazzetti, A.; Rossi, R.; Marchetti, A.; Tinelli, C.; Della Bruna, C.

In: Journal of Antimicrobial Chemotherapy, Vol. 34, No. 5, 1994, p. 649-657.

Research output: Contribution to journalArticle

Olliaro, PB, Gorini, G, Jabes, D, Regazzetti, A, Rossi, R, Marchetti, A, Tinelli, C & Della Bruna, C 1994, 'In-vitro and in-vivo activity of rifabutin against Toxoplasma gondii', Journal of Antimicrobial Chemotherapy, vol. 34, no. 5, pp. 649-657.
Olliaro PB, Gorini G, Jabes D, Regazzetti A, Rossi R, Marchetti A et al. In-vitro and in-vivo activity of rifabutin against Toxoplasma gondii. Journal of Antimicrobial Chemotherapy. 1994;34(5):649-657.
Olliaro, P. B. ; Gorini, G. ; Jabes, D. ; Regazzetti, A. ; Rossi, R. ; Marchetti, A. ; Tinelli, C. ; Della Bruna, C. / In-vitro and in-vivo activity of rifabutin against Toxoplasma gondii. In: Journal of Antimicrobial Chemotherapy. 1994 ; Vol. 34, No. 5. pp. 649-657.
@article{e29b79b3fb304ba898ec523d52718cfd,
title = "In-vitro and in-vivo activity of rifabutin against Toxoplasma gondii",
abstract = "The activity of rifabutin against Toxoplasma gondii was investigated in vitro and in vivo. One set of in-vitro studies used either a low virulence or a high virulence T. gondii strain subcultured in drug-free conditions after exposure to various drug concentrations. No parasite growth was observed after subculture at 1 month after exposure to 6 mg/L of rifabutin for the low virulence and 12 mg/L for the high virulence strain. The IC 50 of rifabutin was 26.5 mg/L in a different series of experiments (using an enzyme-linked immunoassay) and the T. gondii high virulence strain. In similar experiments with clarithromycin, low virulence and high virulence parasites grew in drug-free subcultures following exposure to drug concentrations as high as 100mg/L; the IC 50 of clarithromycin exceeded 100mg/L for the high virulence strain. In the acute toxoplasmosis murine model, mice received a 12 day treatment starting 5 days before infection with high virulence parasites. Survival was significantly improved compared with untreated controls in response to 50, 100 and 200 mg/kg/day rifabutin and 100 and 200 (but not 50) mg/kg/day clarithromycin, and with the combination of the two drugs at 25, 50 and 100 mg/kg/day. Survival was significantly improved when combination therapy was administered. The calculated ED 50 values (mg/kg/day) were 160.5 for rifabutin, 119.4 for clarithromycin, and 114.8 for the combination. In the present experimental conditions rifabutin proved effective in vitro and in vivo against T. gondii and showed potentiation with clarithromycin in vivo.",
author = "Olliaro, {P. B.} and G. Gorini and D. Jabes and A. Regazzetti and R. Rossi and A. Marchetti and C. Tinelli and {Della Bruna}, C.",
year = "1994",
language = "English",
volume = "34",
pages = "649--657",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - In-vitro and in-vivo activity of rifabutin against Toxoplasma gondii

AU - Olliaro, P. B.

AU - Gorini, G.

AU - Jabes, D.

AU - Regazzetti, A.

AU - Rossi, R.

AU - Marchetti, A.

AU - Tinelli, C.

AU - Della Bruna, C.

PY - 1994

Y1 - 1994

N2 - The activity of rifabutin against Toxoplasma gondii was investigated in vitro and in vivo. One set of in-vitro studies used either a low virulence or a high virulence T. gondii strain subcultured in drug-free conditions after exposure to various drug concentrations. No parasite growth was observed after subculture at 1 month after exposure to 6 mg/L of rifabutin for the low virulence and 12 mg/L for the high virulence strain. The IC 50 of rifabutin was 26.5 mg/L in a different series of experiments (using an enzyme-linked immunoassay) and the T. gondii high virulence strain. In similar experiments with clarithromycin, low virulence and high virulence parasites grew in drug-free subcultures following exposure to drug concentrations as high as 100mg/L; the IC 50 of clarithromycin exceeded 100mg/L for the high virulence strain. In the acute toxoplasmosis murine model, mice received a 12 day treatment starting 5 days before infection with high virulence parasites. Survival was significantly improved compared with untreated controls in response to 50, 100 and 200 mg/kg/day rifabutin and 100 and 200 (but not 50) mg/kg/day clarithromycin, and with the combination of the two drugs at 25, 50 and 100 mg/kg/day. Survival was significantly improved when combination therapy was administered. The calculated ED 50 values (mg/kg/day) were 160.5 for rifabutin, 119.4 for clarithromycin, and 114.8 for the combination. In the present experimental conditions rifabutin proved effective in vitro and in vivo against T. gondii and showed potentiation with clarithromycin in vivo.

AB - The activity of rifabutin against Toxoplasma gondii was investigated in vitro and in vivo. One set of in-vitro studies used either a low virulence or a high virulence T. gondii strain subcultured in drug-free conditions after exposure to various drug concentrations. No parasite growth was observed after subculture at 1 month after exposure to 6 mg/L of rifabutin for the low virulence and 12 mg/L for the high virulence strain. The IC 50 of rifabutin was 26.5 mg/L in a different series of experiments (using an enzyme-linked immunoassay) and the T. gondii high virulence strain. In similar experiments with clarithromycin, low virulence and high virulence parasites grew in drug-free subcultures following exposure to drug concentrations as high as 100mg/L; the IC 50 of clarithromycin exceeded 100mg/L for the high virulence strain. In the acute toxoplasmosis murine model, mice received a 12 day treatment starting 5 days before infection with high virulence parasites. Survival was significantly improved compared with untreated controls in response to 50, 100 and 200 mg/kg/day rifabutin and 100 and 200 (but not 50) mg/kg/day clarithromycin, and with the combination of the two drugs at 25, 50 and 100 mg/kg/day. Survival was significantly improved when combination therapy was administered. The calculated ED 50 values (mg/kg/day) were 160.5 for rifabutin, 119.4 for clarithromycin, and 114.8 for the combination. In the present experimental conditions rifabutin proved effective in vitro and in vivo against T. gondii and showed potentiation with clarithromycin in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0028598024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028598024&partnerID=8YFLogxK

M3 - Article

C2 - 7706160

AN - SCOPUS:0028598024

VL - 34

SP - 649

EP - 657

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 5

ER -